FAQ/Help |
Calendar |
Search |
Today's Posts |
07-29-2016, 02:40 PM | #1 | ||
|
|||
Member
|
|
||
Reply With Quote |
07-29-2016, 02:41 PM | #2 | ||
|
|||
Member
|
Modulating global DNA methylation -- either by injecting methionine to increase methylation or applying RG-108, an inhibitor of methylation, to the striatum -- modified the dyskinetic behavior of LID, down or up, respectively.
|
||
Reply With Quote |
08-11-2016, 09:03 AM | #3 | ||
|
|||
Member
|
|
||
Reply With Quote |
08-12-2016, 02:10 AM | #4 | ||
|
|||
Member
|
The article from ScienceDaily says:
"The treatments we have used here, methionine supplementation or RG-108, are not practical for human use; but they point to the opportunity to develop methylation-based epigenetic therapeutics in Parkinson's disease." The message I get from the article is that a new research direction has been established in the battle with LID, but it will be quite a few years before PwPs can expect a new drug to become available (if ever). |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Why brain neurons in Parkinson's disease stop benefiting from levodopa - Science Dail | Parkinson's News | |||
Positive results of new levodopa product for Parkinson's disease | Parkinson's Disease | |||
Does levodopa accelerate the pathologic process in Parkinson disease brain | Parkinson's Disease | |||
A study of Parkinson's disease in Carbidopa And Levodopa: who, when, how? | Parkinson's Disease | |||
Rotigotine As Levodopa Adjunct Is Effective In Advanced Parkinson's Disease | Parkinson's Disease |